Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1354223-67-8

Post Buying Request

1354223-67-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1354223-67-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1354223-67-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,4,2,2 and 3 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1354223-67:
(9*1)+(8*3)+(7*5)+(6*4)+(5*2)+(4*2)+(3*3)+(2*6)+(1*7)=138
138 % 10 = 8
So 1354223-67-8 is a valid CAS Registry Number.

1354223-67-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name tert-butyl N-(2-chloro-5-fluoropyridin-4-yl)carbamate

1.2 Other means of identification

Product number -
Other names TERT-BUTYL 2-CHLORO-5-FLUOROPYRIDIN-4-YLCARBAMATE

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1354223-67-8 SDS

1354223-67-8Downstream Products

1354223-67-8Relevant articles and documents

ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS

-

Page/Page column 119, (2018/02/17)

The invention is directed to substituted isoquinoline derivatives and uses thereof. Specifically, the invention is directed to compounds according to Formula I and the use of compounds of Formula (I) in treating disease states: (I) wherein R1,

TGF BETA RECEPTOR ANTAGONISTS

-

Page/Page column 345; 346, (2017/03/08)

The invention relates generally to compounds that modulate the activity of TGFβR-1 and TGFβ R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1354223-67-8